Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 22, 2025 07:05 ET | Source: Global Market Insights Inc.

Shingles Vaccine Market to hit USD 12.9 billion by 2034, says Global Market Insights Inc.

Selbyville, Delaware, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Shingles vaccine market size was valued at USD 4.9 billion in 2024 and is projected to grow at a robust CAGR of 10.1% from 2025 to 2034. Key...
January 12, 2025 10:00 ET | Source: Curevo Vaccine

Curevo Announces Positive Updated Phase 2 Data for Amezosvatein Shingles Vaccine

Updated Phase 2 data one year after the second vaccine dose, the anti-gE antibody immune response to amezosvatein continues to be non-inferior to Shingrix
January 08, 2025 11:30 ET | Source: Curevo Vaccine

Curevo Vaccine to present at the 43rd Annual J.P. Morgan Healthcare Conference

Curevo Vaccine will present at the 2025 JPM Healthcare Conference on Wednesday January 15th.
October 31, 2024 02:00 ET | Source: Curevo Vaccine

Curevo Presents Positive Shingles Vaccine Outcomes Data

Zero shingles cases after 18.8 months follow-up in 619 patients receiving any dose of amezosvatein, a development-stage adjuvanted subunit vaccine
October 16, 2024 11:00 ET | Source: Curevo Vaccine

Curevo Vaccine Presents Amezosvatein Shingles Vaccine Data at ID Week

Positive data from 876-patient head-to-head trial versus Shingrix® shows amezosvatein elicits robust immune responses with better tolerability.
April 08, 2024 10:00 ET | Source: Curevo Vaccine

Dr. Chi Li Joins Curevo Vaccine as Chief Regulatory Officer

SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus vaccines with improved...
January 07, 2024 11:00 ET | Source: Curevo Vaccine

Curevo Vaccine Announces Positive Topline Results from Phase 2 Trial of Amezosvatein, a Next-Generation Vaccine for Shingles, Head-to-Head vs. Shingrix

-- Positive data from 876-patient head-to-head trial versus Shingrix® shows amezosvatein met the primary immunogenicity endpoint, eliciting a robust immune response non-inferior to Shingrix, including...
March 29, 2022 10:09 ET | Source: Association of American Physicians and Surgeons

Did CDC Suppress Data on Chickenpox Vaccine? Asks Article in Journal of American Physicians and Surgeons

TUCSON, Ariz., March 29, 2022 (GLOBE NEWSWIRE) -- The chickenpox (varicella) vaccine has markedly decreased the incidence of chickenpox. Although chickenpox is almost always a mild disease,...